Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
M&A
Biotech
Gone are the bear days for biotech? William Blair thinks so
The analyst’s optimism is rooted in continued M&A activity, with 2025's biopharma deal volume the highest recorded in the last decade.
Gabrielle Masson
Dec 12, 2025 10:55am
Cycle Pharma scoops up beleaguered rare disease biotech
Dec 12, 2025 9:55am
JSR hands over Crown to Carlyle-backed company in $204M deal
Nov 18, 2025 2:32pm
Repare nails down XenoTherapeutics buyout
Nov 17, 2025 12:12pm
J&J pays $3B cash for Halda's cancer cell death tech
Nov 17, 2025 10:19am
Pfizer finalizes Metsera buy after contentious Novo bidding war
Nov 13, 2025 12:43pm
